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Alemtuzumab is a lymphocyte-depleting monoclonal antibody targeting CD52 and is
a highly effective treatment for relapsing-remitting multiple sclerosis (RRMS).
However, it has a serious safety profile, including autoimmunity, often delayed, in
some 40% of patients.1 We describe an individual in whom fatal inflammatory
myocarditis occurred over 2 years after alemtuzumab.
A 32-year-old previously well man presented with a 4-week episode of subacute-
onset left hemisensory loss, followed by 2 days of painful tonic spasms of the right
hand. MRI scanning showed a right high cervical lesion, together with several white
matter lesions in the brain with characteristics highly suggestive of inflammatory demyelination.
He was treated with a 3-day course of high-dose intravenous methylprednisolone but had
a further episode 2 weeks later, with repeatMRI scanning showingmultiple new lesions. He was
then treated with alemtuzumab, 12 mg daily for 5 days. He had no further clinical episodes, and
repeat MRI brain scanning showed no new lesion formation; he received a second course of
alemtuzumab (12 mg daily for 3 days) 12 months later.
Two years later, he remained relapse free, and repeat MRI brain imaging again showed no new
lesions. However, he developed symptomatic hyperthyroidism with positive antithyroid anti-
bodies; he was treated with carbimazole but rapidly became hypothyroid and required thy-
roxine treatment.
Eight months later, 27 months after his second course of alemtuzumab, he was urgently
admitted with acute severe chest pain, rapidly progressing to cardiogenic shock. Echocardi-
ography confirmed severe biventricular failure with normal vessels on coronary angiography.
He was transferred to a specialist heart hospital where intensive support, including peripheral
venoarterial extracorporal membrane oxygenation, an intra-aortic balloon pump, and the in-
sertion of a left ventricular impella, was instituted, but he developed multiorgan failure and died
3 weeks after admission.
An autopsy study of the heart (figure) revealed complete transmural necrosis with infiltration
by lymphocytes and giant cells throughout the myocardium and widespread necrosis of
myocytes, involving both atria and ventricles. There were no granulomata and no signs of
vasculitis; eosinophils were largely absent. The conclusion was that of fatal giant cell
myocarditis.
Giant cell myocarditis is a rare disorder. We have been unable to identify other cases that have
followed immunosuppressive therapies, and it remains impossible to be certain of a link in the
current case to alemtuzumab treatment last received 27 months earlier. However, the wide
range of autoimmune complications occurring in well over a third of patients receiving alem-
tuzumab,1 some emerging years after treatment, (arguably coupled with the occurrence of
myocarditis only a fewmonths after the development of autoimmune thyroid disease), clearly if
circumstantially implicate alemtuzumab.
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PRACTICAL IMPLICATIONS
The serious, often fatal disorder
giant cell myocarditis may repre-
sent a new autoimmune compli-
cation of alemtuzumab used in
multiple sclerosis.
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Inflammatory myocarditis carries a mortality of some 50%.
Many cases are idiopathic; alternatively, while not reported
after other drugs used for autoimmune disease, inflammatory
myocarditis, including giant cell myocarditis,2 is well recog-
nized if uncommon consequence of immune checkpoint
inhibitors3 used in various malignancies. Perhaps surprisingly,
given our current case description, case reports have appeared
in recent years, indicating that refractory giant cell myocarditis
may be successfully treated with alemtuzumab and calling for
further study of this therapeutic possibility.4,5
We report a case of fatal giant cell myocarditis after alemtuzu-
mab administration in a patient with RRMS. Secondary auto-
immunity is a well-known risk of alemtuzumab, and this case
adds an important new potential side effect to its profile.
Clinicians should be aware of this risk. Alemtuzumab may par-
adoxically be a useful treatment for giant cell myocarditis arising
in other circumstances: that it may trigger this complex heart
disorder should, however, introduce some caution into exploring
its therapeutic potential in autoimmune cardiac disease.
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Figure Autopsy Study of the Heart
Hematoxylin and eosin stained section of the right ventricle showing dead
hypereosinophilic myocytes surrounded by giant cells and lymphocytes











United Kingdom Major role in histopathologic








Major role in histopathologic







details and edited the manuscript
content
Neurology.org/CP Neurology: Clinical Practice | Volume 11, Number 1 | February 2021 e47
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
DOI 10.1212/CPJ.0000000000000772
2021;11;e46-e47 Published Online before print November 11, 2019Neurol Clin Pract 
Neil J. Scolding, Hiam Ali, Mary Sheppard, et al. 
Alemtuzumab and Fatal Myocarditis




including high resolution figures, can be found at:
References
 http://cp.neurology.org/content/11/1/e46.full.html##ref-list-1











its entirety can be found online at:




Information about ordering reprints can be found online:
Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.
since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2019 American Academy of 
is an official journal of the American Academy of Neurology. Published continuouslyNeurol Clin Pract 
